Biologics by McKesson Selected as Limited Distribution Specialty Pharmacy Provider for PHYRAGO™
Effective July 7, Cycle Pharmaceuticals’ PHYRAGO™ (dasatinib) will be supported by Biologics by McKesson as a limited distribution specialty pharmacy partner
DECNUPAZ™(pivekimab sunirine-pvzy), FDA‑Approved for Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Exclusively Available at Biologics by McKesson
Biologics by McKesson became the exclusive specialty pharmacy provider for DECNUPAZ, an intravenous therapy approved for patients with blastic plasmacytoid dendritic cell neoplasm.
Biologics by McKesson’s Pharmacy Elite™ Selected as Hub for Rigel Pharmaceuticals’ Tavalisse®, Gavreto® and Rezlidhia®
Biologics by McKesson’s Pharmacy Elite was selected as Rigel’s hub for Tavalisse, Gavreto, and Rezlidhia, supporting access services including benefits investigation, prior authorization, and financial assistance navigation.
AQVESME® (mitapivat), FDA-Approved for Adults with Thalassemia, Exclusively Available at Biologics by McKesson
Biologics by McKesson became the sole specialty pharmacy provider for AQVESME, indicated for adults with non-transfusion-dependent or transfusion-dependent alpha- or beta-thalassemia.
PALSONIFY™ (paltusotine), FDA-Approved for Treatment of Adults with Acromegaly Who Had an Inadequate Response to Surgery and/or for Whom Surgery Is Not an Option, Available at Biologics by McKesson
Biologics by McKesson was selected as a limited specialty pharmacy provider for PALSONIFY, the first once-daily oral therapy for adults with acromegaly who need an alternative to surgery.
WAYRILZ™ (rilzabrutinib), FDA-Approved for Treatment of Adults with Immune Thrombocytopenia, Available at Biologics by McKesson
Biologics by McKesson was selected as a limited specialty pharmacy provider for WAYRILZ, an oral BTK inhibitor for adults with persistent or chronic immune thrombocytopenia.
PIQRAY® (alpelisib) FDA Approved for the Treatment of Patients with a PIK3CA Mutation in HR+/HER2- Advanced Breast Cancer , Available Exclusively at Biologics by McKesson
Biologics by McKesson became the exclusive specialty pharmacy for PIQRAY, indicated with fulvestrant for adults with PIK3CA-mutated, HR-positive, HER2-negative advanced or metastatic breast cancer.
VIJOICE® (alpelisib) FDA Approved for the Treatment of Patients with PIK3CA-Related Overgrowth Spectrum (PROS), Available Exclusively at Biologics by McKesson
Biologics by McKesson became the exclusive specialty pharmacy for VIJOICE, indicated for adults and children age 2 and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum.
ENSACOVE™ (ensartinib), FDA-Approved Treatment for Adult Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer, Exclusively Available at Biologics by McKesson
Biologics by McKesson became the sole specialty pharmacy provider for ENSACOVE and exclusive hub services provider for adults with advanced ALK-positive non-small cell lung cancer.
AUGTYRO™ (Repotrectinib), FDA Approved for Treatment of AdvancedROS1-Positive & NTRK-Positive NSCLC, Available at Biologics by McKessonSpecialty Pharmacy in Limited Distribution Network
Biologics by McKesson joined the limited distribution network for AUGTYRO, approved for ROS1-positive non-small cell lung cancer and certain NTRK gene fusion-positive solid tumors.